- $5.3 BnWorld market, 2023
- $25 BnProjected, 2033
- 16.8%Growth a year (CAGR)
- 258Active clinical trials worldwide
Largest countries
Market size in 2023 · growth a year to 2033
-
1
US
$2.2 Bn
14.8% a year · 42% of the world -
2
China
$426 Mn
18.3% a year · 8% of the world -
3
Canada
$424 Mn
16.8% a year · 8% of the world -
4
Japan
$329 Mn
17.3% a year · 6.2% of the world -
5
Germany
$194 Mn
15% a year · 3.7% of the world -
6
France
$146 Mn
15.8% a year · 2.7% of the world -
7
UK
$138 Mn
14.8% a year · 2.6% of the world -
8
Brazil
$133 Mn
17.8% a year · 2.5% of the world -
9
Italy
$127 Mn
16.3% a year · 2.4% of the world -
10
Ecuador
$106 Mn
17.4% a year · 2% of the world
Most clinical trials
Active trials by country (ClinicalTrials.gov)
See every trial on ClinicalTrials.gov (opens in a new tab)Cannabidiol (CBD) Supplements by country and region
Spain
India
Saudi Arabia
Mexico
Australia
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya
New Zealand
Russia"–" means we have no size for that place yet. 2033 values are projected from the 2023 size and the CAGR. Regions count only the countries we report on for trials.
Latest research 5,450 papers since 2021
- Assessment of Δ(9)-tetrahydrocannabiphorol (THCP), Δ(8)-tetrahydrocannabinol (Δ(8)-THC), and cannabinol (CBN) pharmacodynamics and pharmacokinetics across multiple routes of administration in the C57BL/6 mouse. European journal of pharmacology, 2026
- Cannabis sativa and the endocannabinoid system in cervical cancer: molecular targets and mechanistic insights from preclinical models-narrative review. Journal of cannabis research, 2026
- GAT1508, a selective neuronal GIRK1/2 activator, exhibits superior antiepileptic efficacy and synergizes with cannabidiol. bioRxiv : the preprint server for biology, 2026
- Studying the pharmacological interaction of temozolomide chemotherapy with different antidepressant treatments in a rat glioblastoma model. Neuroscience, 2026
- Hemp bark extract attenuates scopolamine-induced cognitive dysfunction through multi-target cholinesterase, MAO-B, and antioxidant mechanisms. Biochemistry and biophysics reports, 2026
Compare Cannabidiol (CBD) Supplements side by side
Key companies in Cannabidiol (CBD) Supplements
Aphria Inc
Canopy Growth Corporation CV Sciences
Elixinol Global Limited
Freedom Leaf Inc
Folium Biosciences
Green Roads of Florida
Isodiol International Inc
Medical Marijuana Inc
Nano Hydrate
Quick answers
How big is the Cannabidiol (CBD) Supplements market?
The world Cannabidiol (CBD) Supplements market was worth about $5.3 Bn in 2023 and is projected to reach $25 Bn by 2033, growing 16.8% a year (CAGR).
Which country has the largest Cannabidiol (CBD) Supplements market?
The US is the largest of the 24 countries we cover, at $2.2 Bn in 2023. India grows fastest, at 19.8% a year.
How many clinical trials are running in Cannabidiol (CBD) Supplements?
ClinicalTrials.gov lists 258 active trials worldwide (recruiting, about to start or running), most of them in the US, as of 10 Nov 2026.
How much research is published on Cannabidiol (CBD) Supplements?
PubMed lists about 5,450 papers on the topic since 2021.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov. Research: PubMed (US National Library of Medicine). Fetched 10 Nov 2026. Trials and papers are found by search words, so counts are a guide.